APPRILON CAPSULE (IMMEDIATE AND DELAYED RELEASE)

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

DOXYCYCLINE (DOXYCYCLINE MONOHYDRATE)

Prieinama:

GALDERMA CANADA INC

ATC kodas:

J01AA02

INN (Tarptautinis Pavadinimas):

DOXYCYCLINE

Dozė:

40MG

Vaisto forma:

CAPSULE (IMMEDIATE AND DELAYED RELEASE)

Sudėtis:

DOXYCYCLINE (DOXYCYCLINE MONOHYDRATE) 40MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

14/28

Recepto tipas:

Prescription

Gydymo sritis:

TETRACYCLINES

Produkto santrauka:

Active ingredient group (AIG) number: 0105569008; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2011-11-14

Prekės savybės

_ _
_APPRILON Product Monograph _
_Page 1 of 28_
PRODUCT MONOGRAPH
Pr
APPRILON
®
Doxycycline
Modified-Release Capsule, 40 mg
(as doxycycline monohydrate)
Anti-Rosacea
GALDERMA CANADA INC.
55 Commerce Valley Dr. W., 4th floor
Thornhill, Ontario L3T 7V9
Date of Preparation:
November 09, 2011
Date of Revision:
May 31, 2018
Submission Control No: 214275
_ _
_APPRILON Product Monograph _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND ADMINISTRATION
..............................................................................12
OVERDOSAGE
................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................17
PHARMACEUTICAL INFORMATION
..........................................................................17
CLINICAL TRIALS
....................................................................................